PregLem – Acquired by the Richter Group in 2010 for 445 million Swiss Francs. PregLem SA is a Swiss-based specialty Biopharma company dedicated to the development and commercialization of innovative drugs for women’s reproductive medicine. PregLem’s activities focus on developing therapies for gynecologic conditions with significant unmet needs and that have a severe impact on the patient’s quality of life: uterine fibroids, endometriosis, infertility through ovarian reserve modulation, and post surgical adhesions.